# Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years

> **NCT04956224** · PHASE3 · COMPLETED · sponsor: **Valneva Austria GmbH** · enrollment: 306 (actual)

## Conditions studied

- SARS-CoV-2 Virus Infection

## Interventions

- **BIOLOGICAL:** VLA2001

## Key facts

- **NCT ID:** NCT04956224
- **Lead sponsor:** Valneva Austria GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-09
- **Primary completion:** 2021-11-10
- **Final completion:** 2022-11-18
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2023-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04956224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04956224, "Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04956224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*